

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**In re Applicant:**

Zvi SIDELMAN

Serial No.: 09/942,121

Filed: August 30, 2001

For: Casein Derived Peptides And Uses  
Thereof In Therapy

Examiner:

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450



Group Art Unit: 1614

Attorney  
Docket: 01/22453

# INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted,

  
Sol Sheinbein  
Registration No. 25,457

Date: August 30, 2004

Please type a plus sign (+) inside this box → +

Approved for use through 10/31/99 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				Complete if Known Application Number      09/942,121 Filing Date      08/30/2001 First Named Inventor      Sidelman Group Art Unit      1653 Examiner Name      Liu				
Sheet	1	Of	4	Attorney Docket Number      01/22453				
U.S. PATENT DOCUMENTS								
Examiners Initials	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear		
		Number	Kind Code <sup>2</sup> (if known)					
		5,147,853		Dosako et al.	09-15-1992			
		5,344,820		Dosako et al.	09-06-1994			
		5,330,975		Isoda et al.	07-19-1994			
		3,764,670		Katzir-Katchalsky et al	10-09-1993			
		6,570,060		McLachlan	05-27-2003			
		5,707,968		Mukerji et al.	01-13-1998			
		5,538,952		Mukerji et al.	07-23-1996			
		5,506,209		Mukerji et al.	04-09-1996			
		5,712,250		Mukerji et al.	01-07-1998			
		5,985,275		Neurath et al.	11-16-1999			
		6,495,344		Carr et al	12-17-2002			
		20030195150		Reynolds et al	10-16-2003			
		6,180,761		Han et al	01-30-2001			
		5,846,732		Collin et al	12-08-1998			
		20040002118		Smilansky	01-01-2004			
FOREIGN PATENT DOCUMENTS								
Examiners Initials	Cite No. <sup>1</sup>	Foreign Patent Documents			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
		JP	3476516		Takenaka	12-10-2003		
		WO	03/093308		Juillerat et al	11-13-2003		
Examiner Signature						Date Considered		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box →

Approved for use through 10/31/99 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (10-96)

SEP 01 2004

PATENT & TRADEMARK OFFICE

Substitute for form 1449A/PTO

Complete if Known

Application Number	09/942,121
Filing Date	08/30/2001
First Named Inventor	Sidelman
Group Art Unit	1653
Examiner Name	Liu

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	2	Of	4	Attorney Docket Number	01/22453
-------	---	----	---	------------------------	----------

### OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Alexander et al., "Isolation and characterization of the bovine kappa-casein gene", Eu J Biochem 178: 395-401, 1988. (abstract)	
		American Health Consultants, "New Drugs, New Data Hold Promise for Next Decade of HIV Treatment", AIDS Alert, 2002. 9 <sup>th</sup> Conference on Retroviruses.	
		Carles et al., "Kinetics of the action of chymosin (rennin) on a peptide bond of bovine alpha s1-casein. Comparison of the behaviour of this substrate with that of beta- and kappa o-caseins", FEBS Lett. 1985 Jun 17;185(2):282-6. (abstract).	
		Chabance et al., "Casein Peptide Release and Passage to the Blood in Humans During Digestion of Milk or Yoghurt", Biochimie, 80(2): 155-165, 1998.	
		Chabance et al., "Binding of the bovine caseinoglycopeptide to the platelet membrane glycoprotein GPIb alpha", Biochem Mol Biol Int. 1997 Jun;42(1):77-84. (abstract)	
		Coste et al., "Identification of C-terminal peptides of bovine beta-casein that enhance proliferation of rat lymphocytes", Immunol Lett. 1992 Jun;33(1):41-6. .	
		Fiat et al., "Biologically Active Peptides From Milk Proteins With Emphasis on Two Examples Concerning Antithrombotic and Immunomodulating Activities", J. Dairy Sci., 76: 301-310, 1993.	
		Giannoukakis et al., "Gene and Cell Therapies for Diabetes Mellitus", Biodrugs 16(3): 149-173, 2002"	
		Groenen et al., "The complete sequence of the gene encoding bovine alpha s2-casein. Gene", 1993 Jan 30;123(2):187-93. (abstract)	
		Kim et al., "Genetic Models for Non Insulin Dependent Diabetes Mellitus in Rodents", Journal of Basic & Clinical Physiology & Pharmacology 9(2-4): 325-345, 1998.	
		Kitts, "Bioactive substances in food: identification and potential uses", Can J Physiol Pharmacol. 1994 Apr;72(4):423-34. (abstract)	
		Koczan et al., "Genomic organization of the bovine alpha-S1 casein gene", Nucleic Acids Res. 1991 Oct 25;19(20):5591-6.	
		Lahov et al., Antibacterial and Immunostimulating Casein-Derived Substances From Milk: Casecidin, Isracidin Peptides", Food and Chemical Toxicology, 34(1): 131-145, 1996.	
		Laugesen, "The Influence of Consumption of A1 Beta-Casein on Heart Disease and Type 1 Diabetes-The Authors Reply", NZ Med J 16(1170):U295, 2003.	
		Malkoski et al., "Kappacin, a novel antibacterial peptide from bovine milk", Antimicrob Agents Chemother. 2001 Aug;45(8):2309-15.	
		Marmor et al., "Homozygous and Heterozygous CCR5-Delta32 Genotypes are Associated with Resistance to HIV Infection", JAIDS 27: 472-481, 2001.	
		McSweeney et al., "Proteolytic specificity of chymosin on bovine alpha s1-casein", J Dairy Res. 1993 Aug;60(3):401-12. (abstract)	
Examiner Signature		Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.


Please type a plus sign (+) inside this box →

Approved for use through 10/31/99 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (10-96)



Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	3	Of	4	Attorney Docket Number
				01/22453
		Meisel et al., "Bioactive Peptides Encrypted in Milk Proteins: Proteolytic Activation and Thropho-Functional Properties", Antonie Van Leeuwenhoek, 76(1-4): 207-15, 1999. (abstract)		
		Michaelidou et al., "Isolation and Identification of Some Major Water-Soluble Peptides in Feta Cheese", J. Dairy Sci., 81: 3109-3116, 1998.		
		Nolan et al., "Antiretroviral Prophylaxis of Perinatal HIV-1 Transmission and the Potential Impact of Antiretroviral Resistance", JAIDS 30: 216-229, 2002.		
		Notterpek et al., "Experimental Models of Peripheral Neuropathies", Laboratory Animal Science 49(6): 588-599, 1999.		
		Pahkala et al., "Decomposition of Milk Proteins During the Ripening of Cheese 1. Enzymatic Hydrolysis of Alpha-S Casein", Meijeritieteellinen Aikakauskirja, 47(1): 39-47, 1989.		
		Prud'homme, "Gene Therapy of Autoimmune Diseases with Vectors Encoding Regulatory Cytokines or Inflammatory Cytokine Inhibitors", The Journal of Gene Medicine 2: 222-232, 2000.		
		Rattray et al., "Specificity of an Extracellular Proteinase From <i>Brevibacterium Linens</i> ATCC", Applied and Environmental Microbiology, 62(2): 501-506, 1996.		
		Rota et al., "Characterization of a novel coronavirus associated with severe acute respiratory syndrome", Science. 2003 May 30;300(5624):1394-9. Epub 2003 May 01.		
		Shimizu et al., "Emulsifying Properties of an N-Terminal Peptide Obtained From the Peptic Hydrolyzate of Alphas1-Casein", Journal of Food Science, 49(4): 1117-1120, 1984.		
		Sriwanthana et al., "HIV-Specific Cytotoxic T Lymphocytes, HLA-A11, and Chemokine-Related Factors May Act Synergistically to Determine HIV Resistance in CCR Delta32-Negative Female Sex Workers in Chiang Rai, Northern Thailand", AIDS Research and Human Retroviruses 17(8): 719-734, 2001.		
		von dem Borne et al., "Thrombopoietin: Modes of Action, Role in Platelet Disorders and New Drugs", Academic Medical Center, Amsterdam.		
		Wong et al., "Insulin-Dependent Diabetes Mellitus and its Animal Models", Current Opinion in Immunology 11: 643-647, 1999.		
		Yoon et al., "Cellular and Molecular Pathogenic Mechanisms of Insulin-Dependent Diabetes Mellitus", Annals New York Academy of Science, pp: 200-211.		
		Yvon et al., "Solubility of peptides in trichloroacetic acid (TCA) solutions. Hypothesis on the precipitation mechanism", Int J Pept Protein Res. 1989 Sep;34(3):166-76. (abstract)		
		Mercier et al., "Construction and identification of recombinant plasmids carrying cDNAs coding for ovine alpha S1-, alpha S2-, beta-, kappa-casein and beta-lactoglobulin. Nucleotide sequence of alpha S1-casein cDNA", Biochimie. 1985 Sep;67(9):959-71. (abstract)		
Examiner Signature				Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.


DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

Approved for use through 10/31/99 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



PTO/SB/08A (10-96)

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	4	Of	4	Complete if Known	
				Application Number	09/942,121
				Filing Date	08/30/2001
				First Named Inventor	Sidelman
				Group Art Unit	1653
				Examiner Name	Liu
Sheet	4	Of	4	Attorney Docket Number	01/22453
		Exterkate et al, "Diversity of cell envelope proteinase specificity among strains of Lactococcus lactis and its relationship to charge characteristics of the substrate-binding region", Appl Environ Microbiol. 1993 Nov;59(11):3640-7.			
		Nakajima-Adachi et al, "Determinant analysis of IgE and IgG4 antibodies and T cells specific for bovine alpha(s)1-casein from the same patients allergic to cow's milk: existence of alpha(s)1-casein-specific B cells and T cells characteristic in cow's-milk allergy", J Allergy Clin Immunol. 1998 May;101(5):660-71. (abstract)			
		Pizzano et al, "Antipeptide Antibodies as Analytical Tools To Discriminate among Bovine alpha(s1)-Casein Components", J Agric Food Chem. 1998 Feb 16;46(2):766-771. (abstract)			
		Hachimura et al, "Differential inhibition of T and B cell responses to individual antigenic determinants in orally tolerized mice", Int Immunol. 1994 Nov;6(11):1791-7. (abstract)			
		Ametani et al, "Antibody response of three different strains of mice to alpha s1-casein analyzed by using proteolytic and synthetic peptides", Biochem Biophys Res Commun. 1988 Aug 15;154(3):876-82. (abstract)			
		Saito et al, "Isolation and structural analysis of antihypertensive peptides that exist naturally in Gouda cheese", J Dairy Sci. 2000 Jul;83(7):1434-40. (abstract)			
		Perich et al, "Epitope analysis of the multiphosphorylated peptide alpha s1-casein (59-79)", J Pept Sci. 1999 May;5(5):221-33. (abstract)			
		Considine et al, "Proteolytic Specificity of Cathepsin G on Bovine $\alpha_{s1}$ - and $\beta$ -Casins", Food Chemistry, 76(1):59-67, 2002 (abstract)			
		Koka et al, "Investigation of the Ability of a Purified Protease from <i>Pseudomonas Fluorescens</i> RO98 to Hydrolyze Bitter Peptides from Cheese", Int Dairy J., 10(1-2):75-79, 2000, (abstract)			
Examiner Signature				Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>. Unique citation designation number. <sup>2</sup>. Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.